Browsing by Author Hughes, Michael D.
Showing results 1 to 3 of 3
| Issue Date | Title | Author(s) |
| 2024-05-13 | Effectiveness of Double-Dose Dolutegravir in people receiving rifampin-based tuberculosis treatment: an observational, cohort study of people with HIV From 6 Countries | Shah, N. Sarita; Kityo, Cissy; Hughes, Michael D.; McCarth, Caitlyn; Wallis, Carole L.; Hosseinipour, Mina C.; Langat, Deborah; Nyirenda, Mulinda; Rassoo, Mohammed; Dawson, Rodney; Joseph, Yvetot; Some, Fatma; Mngqibisa, Rosie; Mukwekwerere, Pamela Grace; Woolley, Elizabeth; Godfrey, Catherine; Manabe, Yukari C.; Mellors, John W.; Flexner, Charles; Maartens, Gary |
| 2022 | Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial | Avihingsanon1, Anchalee; Hughes, Michael D.; Salata, Robert; Godfrey, Catherine; McCarthy, Caitlyn |
| 2022-06 | Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial | Avihingsanon, Anchalee; Hughes, Michael D.; Salata, Robert; Godfrey, Catherine; McCarthy, Caitlyn; Mugyenyi, Peter |
